Pfizer Planning to Ask FDA to Authorize Fourth COVID Vaccine Dose because First Three Didn't Work



Pfizer <u>announced</u> on Sunday it plans to ask U.S. regulators to grant emergency use authorization of a fourth dose of its COVID vaccine in an effort to maintain manageable levels of hospitalizations and mild infections.

"I think we're going to <u>submit to FDA</u> a significant progress of data about the need for a fourth dose, and they need to make their own conclusions, of course, and then CDC also. [...] It's clear that there is a need in an environment of omicron to boost the immune response," Bourla said in an interview on "<u>Squawk Box</u>."

Bourla <u>said</u> many more variants are coming and Omicron was the first variant to evade the vaccine. Protection after three doses is "not that good against infections" and "doesn't last very long" when faced with a variant like Omicron, Bourla said. So, a fourth dose is "necessary for right now."

Bourla reiterated his company's goal of creating a vaccine effective against all COVID variants for longer periods of time.

"We are working very diligently right now ... to make not only a vaccine that will protect against all variants, including omicron, but also something that can protect for at least a year," he said. "And if we be able to achieve that, then I think it is very easy to follow and remember so that we can go back to really the way used to live."

To be clear, a fourth dose <u>won't prevent COVID</u> (although Pfizer <u>lied to the FDA</u> and said it would) or <u>transmission of</u> <u>the virus</u>, nor will it prevent severe to moderate COVID in anyone who already has <u>natural immunity</u> – which is the vast majority of the American population at this point – nor has it been shown Pfizer's COVID vaccine has the propensity to reduce the severity of anything via the gold standard trials that set the standards for evidence-based medicine.

What we do know is that Pfizer's COVID vaccine is associated with very <u>severe adverse events</u> and the <u>risk of adverse events</u> increases with subsequent injections. We also know that the contents of the shot do not stay at the injection site – and so does Pfizer.

Pfizer plans to create a lucrative vaccine treadmill

From the very beginning, Pfizer has had a billion-dollar plan to create a COVID vaccine treadmill with the goal of ensuring a consistent and indefinite revenue stream.

First, we were told we would only need two doses of Pfizer's COVID vaccine to prevent COVID. Then we were told the vaccine doesn't prevent COVID, but it could keep us from spreading

COVID to others.

Then we were told it actually doesn't <u>prevent transmission</u> of COVID or the disease itself, but it would prevent severe infection resulting in hospitalization or death — but only temporarily. When fully vaccinated people <u>started dying</u> from COVID, we were told the effectiveness of the vaccine wanes, which is why a third dose was needed. When protection from the booster rapidly waned, we were told regular boosters would be needed indefinitely.

In September 2021, the Centers for Disease Control and Prevention (CDC) caused an uproar after it changed its definitions of "vaccination" and "vaccine," – removing the term "immunity" to underscore the rising number of <u>breakthrough COVID cases</u> occurring in the fully vaccinated.

The agency said it <u>altered the definition</u> of "vaccine" out of concern it didn't apply to COVID vaccines, according to <u>internal emails</u> obtained through a Freedom of Information Act request.

Now we're being told that dose one, two and three failed, so a fourth dose of the same vaccine that didn't work the first three times is needed.

Back in February 2021, Bourla said publically he envisioned a world where COVID vaccines would be given annually.

"Every year, you need to go to get your <u>flu vaccine</u>," Bourla said. "It's going to be the same with COVID. In a year, you will have to go and get your annual shot for COVID to be protected," Bourla <u>told</u> NBC News.

During a February earnings call in 2021, Pfizer CEO Albert Bourla <u>told</u> analysts, big banks and investors that as the initial demand for its COVID vaccine subsides, the company could make significant profits by charging higher prices and implementing routine booster doses for new variants of the virus.

During the <u>Barclays' Global Health Conference</u>, CFO Frank D'Amelio said the company doesn't see this as a one-time event, but "as something that's going to continue for the foreseeable future."

Thousands "reportedly" injured by Pfizer's COVID vaccine

One of the most alarming things about authorizing yet another dose of Pfizer's COVID vaccine is that thousands of people have been seriously injured or killed by the first three doses.

The Centers for Disease Control and Prevention (CDC) on March 11 released new data showing a total of <u>1,168,894 reports of</u> <u>adverse events</u> following COVID vaccines were submitted between Dec. 14, 2020, and March 4, 2022, to the Vaccine Adverse Event Reporting System (VAERS). VAERS is the primary governmentfunded system for reporting adverse vaccine reactions in the U.S.

The data included a total of 25,158 reports of deaths – and 203,888 reports of serious injuries, including deaths, during the same time period.

Of the total adverse events reported, 667,973 are <u>attributed</u> to Pfizer's COVID vaccine. Of the 25,158 reported deaths following COVID vaccines, 16,475 are <u>attributed</u> to Pfizer's vaccine.

However, historically, VAERS has been shown to report only $\frac{1\%}{1\%}$ of actual vaccine adverse events.

According to Pfizer, who applied for an <u>FDA waiver</u> to avoid recording certain safety data on the injections because they claimed the VAERS system was adequate in revealing any safety issues with the injections.

VAERS is a "robust" system that is "designed to detect safety concerns with vaccines," according to Pfizer.

In its waiver request, Pfizer stated, VAERS is a "robust" system that is "designed to detect safety concerns with vaccines."

Pfizer also opted out of having an FDA-designated suffix that would help "ensure safe dispensing practices and optimal pharmacovigilance" because the VAERS system was "adequate" and any other safety reporting requirements would be "redundant and burdensome."

The mainstream media has spent a year disparaging VAERS data and acting as if it was not as significant as it really was, said <u>Steve Kirch</u>, founder of the COVID-19 Early Ttreatment Fund in a recent Substack post. "It's amazing how reliable and accurate VAERS is, but when there are adverse safety signals, then VAERS is junk.

Pfizer's own <u>reactogenicity data</u> show people who received Pfizer's COVID vaccine were anywhere from twice to 25 or more times as likely to have severe systemic events compared with the placebo group.

For example, within seven days after each dose, <u>twice as many</u> <u>people</u> (23%) in the vaccinated group suffered systemic events compared with the placebo group (11.3%), while severe fever was reported in the vaccinated group 14 times as often as the placebo group.

What we know is that people are being seriously injured and many are dying at the hands of Pfizer's COVID vaccine, yet instead of pulling the vaccine and acknowledging these injuries, Pfizer is moving full-steam ahead with getting a fourth dose added to the regimen — and it doesn't appear U.S. health agencies are going to stop it.